Omada Health (OMDA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Election of two Class I directors, Sean Duffy and Trevor Fetter, to serve until the 2029 Annual Meeting and until successors are elected and qualified.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Audit committee and external auditor matters
Deloitte & Touche LLP proposed for ratification as the independent auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Omada Health
- Q1 2026 revenue up 42%, members up 51%, margin expansion, and raised outlook on PBM and clinical gains.OMDA
Q1 20268 May 2026 - 53% revenue growth, margin expansion, and new programs set up strong 2026 outlook.OMDA
Q4 202530 Apr 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance and oversight.OMDA
Proxy filing28 Apr 2026 - 52% revenue growth, 886,000 members, and new GLP-1 prescribing drive Omada's momentum.OMDA
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - GLP-1 prescribing and AI-driven care are driving growth, efficiency, and expanded market opportunities.OMDA
Evercore ISI 8th Annual HealthCONx Conference13 Dec 2025 - IPO seeks $133M+ to fund growth; strong revenue, large market, but not yet profitable.OMDA
Registration Filing29 Nov 2025 - 38% revenue growth in 2024, strong retention, but still unprofitable; IPO to fund expansion.OMDA
Registration Filing29 Nov 2025 - Q2 2025 revenue rose 49% to $61.4M, margin expanded, and net loss narrowed to $5.3M.OMDA
Q2 202523 Nov 2025 - Q3 2025 delivered record revenue and member growth, positive adjusted EBITDA, and raised guidance.OMDA
Q3 202513 Nov 2025